# Natera
Who / What
Natera, Inc. is an American clinical genetic testing company specializing in non-invasive cell-free DNA (cfDNA) testing technology. Its innovations focus on women’s health, cancer detection, and organ health by leveraging advanced molecular biology techniques and bioinformatics software to detect even single molecules of DNA from a blood sample.
Background & History
Natera was established as a clinical genetic testing pioneer in Austin, Texas. Founded with the mission to revolutionize personalized healthcare through non-invasive diagnostics, it developed proprietary technology capable of detecting minute traces of cfDNA—a breakthrough that avoids invasive procedures like biopsies. The company has grown from early research into commercializing its platform for applications across oncology, prenatal screening, and organ health monitoring.
Why Notable
Natera’s groundbreaking approach to genetic testing sets a new standard in precision medicine by enabling early cancer detection and personalized healthcare without traditional tissue sampling. Its technology has been pivotal in advancing non-invasive prenatal testing (NIPT) and expanding access to critical diagnostics for women and patients at risk of diseases like breast or ovarian cancer.
In the News
Recently, Natera has gained attention for its continued innovation in cfDNA-based diagnostics, including partnerships with major healthcare providers and FDA approvals for expanded applications. Its work in early cancer detection remains a focal point, reflecting growing demand for non-invasive, high-accuracy screening solutions in an evolving medical landscape.
